



Yposkesi announces the appointment of 3 new members to its Executive Committee

- **Jean-François CHAUBARD, as Gene Therapy Operation Director**
 - **Catherine JOMARY, as Cell Therapy Operation Director**
 - **Denis RIGOLET, as Head of Quality Systems**

Evry, France, May 30th, 2017 - Yposkesi, the first French pharmaceutical company to develop and manufacture gene and cell therapy products for rare diseases, created by the nonprofit organization AFM-Téléthon and the SPI fund managed by Bpifrance, announced today the appointment of 3 new members to its Executive Committee: **Jean-François Chaubard, Catherine Jomary and Denis Rigolet**. The company, which was created in November 2016, is thereby reinforcing its existing Executive Committee headed by Alain Lamproye, CEO.

Jean-François Chaubard, Gene Therapy Operation Director



Jean-François Chaubard has been working in the field of bioprocess technologies for 20 years, including 15 years in the management of multicultural teams. Prior to joining Yposkesi, he held several executive positions during 10 years at GSK Vaccines in Belgium where he was in charge of process industrialization for gene and viral vaccines operations. He had previously managed R&D teams in cell culture at Sanofi Pasteur and CMC Biopharmaceuticals in Denmark. Jean-François holds a MSc from INSA Toulouse in Biochemical Engineering Science (1996).

Catherine Jomary, Cell Therapy Operation Director



Catherine Jomary has been working for 25 years in research discovery and development for cell and gene therapy both in academic and private sectors. Prior to joining Yposkesi, she was in charge of the Cell Therapy Development Department at Roslin Cells and had previously managed the innovation for the production of clinical batches in gene therapy at MeiraGTx (UK). Pr. Jomary also managed QC teams at Baxter Biosciences and R&D teams at ThromboGenics (Belgium). She also created the cell therapy biotechnology company Cell Lab in the UK. Before becoming a teacher-researcher at Kings College London, she was a post-doctoral research fellow at the University of Texas (Houston, USA), at John Hopkins University (Baltimore, US) and at McGill University (Montréal, Canada). She holds a PhD in Molecular Neuro-Pharmacology from the University Paul Sabatier in Toulouse (1987) and is the author of over 50 scientific publications.

Denis Rigolet, Head of Quality Systems



Denis Rigolet brings more than 30 years of experience in the pharmaceutical industry and has held several positions of Quality and Production Director, namely at Stallergenes where he managed a team of over 50 people dedicated to quality systems management and GMP compliance throughout the production process. He also worked within other major pharmaceutical companies such as Sanofi Pasteur, Anteis France, Teva Classics, MerckSerono and Baxter. Denis Rigolet graduated from the University of Liege (Belgium) in 1988 with a Master of Industrial Pharmacy.

"We are thrilled to welcome these 3 new members to our Executive Committee. With their professional background and industry know-how, there is no doubt that they will become key to the development of Yposkesi, which is aiming at European leadership in the development and manufacturing of gene and cell therapy products," said Alain Lamproye, CEO of Yposkesi.

"The significant industrial experience of Catherine Jomary, Jean-François Chaubard and Denis Rigolet as well as their expertise in innovative biotherapy products will be major assets for Yposkesi and its partners", concluded Frédéric Revah, President of Yposkesi.

ABOUT YPOSKESI

Yposkesi (from the Greek Yposchesi, meaning 'promise') is the first French company to develop and produce gene and cell therapy products. Created in November 2016 by AFM-Téléthon and by the SPI fund managed by Bpifrance, this new company aims to make the first treatments available to patients and market them at a fair and controlled price, in accordance to the commitment made by its founders. Located in Evry (Essonne, France), this industrial platform is made up of more than 130 experts in bioproduction and has a first production building covering 5,000 m² (formerly Généthon Bioprod). It is aiming at European leadership and, with this objective, by 2021 will bring together nearly 300 engineers, pharmacists, technicians and experts in three production buildings totaling 13,000 m². It will thus meet the needs of AFM-Téléthon laboratories (Généthon and CECS/I-Stem), as well as those of academic and industrial biotechnology organizations, for clinical trials or post-MA (Marketing Authorization) distribution.

More information at www.yposkesi.com

PRESS CONTACTS

ALIZE RP

Caroline Carmagnol & Margaux Pronost

Mail : yposkesi@alizerp.com

Tél. : +33 1 44 54 36 66